Advanced

EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis

Yates, M.; Watts, R. A.; Bajema, I. M.; Cid, M. C.; Crestani, B.; Hauser, T.; Hellmich, B.; Holle, J. U.; Laudien, M. and Little, M. A., et al. (2016) In Annals of the Rheumatic Diseases 75(9). p.1583-1594
Abstract

In this article, the 2009 European League Against Rheumatism (EULAR) recommendations for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) have been updated. The 2009 recommendations were on the management of primary small and medium vessel vasculitis. The 2015 update has been developed by an international task force representing EULAR, the European Renal Association and the European Vasculitis Society (EUVAS). The recommendations are based upon evidence from systematic literature reviews, as well as expert opinion where appropriate. The evidence presented was discussed and summarised by the experts in the course of a consensus-finding and voting process. Levels of evidence and grades of... (More)

In this article, the 2009 European League Against Rheumatism (EULAR) recommendations for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) have been updated. The 2009 recommendations were on the management of primary small and medium vessel vasculitis. The 2015 update has been developed by an international task force representing EULAR, the European Renal Association and the European Vasculitis Society (EUVAS). The recommendations are based upon evidence from systematic literature reviews, as well as expert opinion where appropriate. The evidence presented was discussed and summarised by the experts in the course of a consensus-finding and voting process. Levels of evidence and grades of recommendations were derived and levels of agreement (strengths of recommendations) determined. In addition to the voting by the task force members, the relevance of the recommendations was assessed by an online voting survey among members of EUVAS. Fifteen recommendations were developed, covering general aspects, such as attaining remission and the need for shared decision making between clinicians and patients. More specific items relate to starting immunosuppressive therapy in combination with glucocorticoids to induce remission, followed by a period of remission maintenance; for remission induction in lifethreatening or organ-threatening AAV, cyclophosphamide and rituximab are considered to have similar efficacy; plasma exchange which is recommended, where licensed, in the setting of rapidly progressive renal failure or severe diffuse pulmonary haemorrhage. These recommendations are intended for use by healthcare professionals, doctors in specialist training, medical students, pharmaceutical industries and drug regulatory organisations.

(Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Annals of the Rheumatic Diseases
volume
75
issue
9
pages
1583 - 1594
publisher
British Medical Association
external identifiers
  • Scopus:84978946297
ISSN
0003-4967
DOI
10.1136/annrheumdis-2016-209133
language
English
LU publication?
yes
id
cf291c67-5b10-4fb8-ac0b-827e14a6e097
date added to LUP
2016-09-08 15:05:16
date last changed
2017-02-26 04:40:54
@article{cf291c67-5b10-4fb8-ac0b-827e14a6e097,
  abstract     = {<p>In this article, the 2009 European League Against Rheumatism (EULAR) recommendations for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) have been updated. The 2009 recommendations were on the management of primary small and medium vessel vasculitis. The 2015 update has been developed by an international task force representing EULAR, the European Renal Association and the European Vasculitis Society (EUVAS). The recommendations are based upon evidence from systematic literature reviews, as well as expert opinion where appropriate. The evidence presented was discussed and summarised by the experts in the course of a consensus-finding and voting process. Levels of evidence and grades of recommendations were derived and levels of agreement (strengths of recommendations) determined. In addition to the voting by the task force members, the relevance of the recommendations was assessed by an online voting survey among members of EUVAS. Fifteen recommendations were developed, covering general aspects, such as attaining remission and the need for shared decision making between clinicians and patients. More specific items relate to starting immunosuppressive therapy in combination with glucocorticoids to induce remission, followed by a period of remission maintenance; for remission induction in lifethreatening or organ-threatening AAV, cyclophosphamide and rituximab are considered to have similar efficacy; plasma exchange which is recommended, where licensed, in the setting of rapidly progressive renal failure or severe diffuse pulmonary haemorrhage. These recommendations are intended for use by healthcare professionals, doctors in specialist training, medical students, pharmaceutical industries and drug regulatory organisations.</p>},
  author       = {Yates, M. and Watts, R. A. and Bajema, I. M. and Cid, M. C. and Crestani, B. and Hauser, T. and Hellmich, B. and Holle, J. U. and Laudien, M. and Little, M. A. and Luqmani, R. A. and Mahr, A. and Merkel, P. A. and Mills, J. and Mooney, J. and Segelmark, M. and Tesar, V. and Westman, K. and Vaglio, A. and Yalçindag, N. and Jayne, D. R. and Mukhtyar, Chetan},
  issn         = {0003-4967},
  language     = {eng},
  number       = {9},
  pages        = {1583--1594},
  publisher    = {British Medical Association},
  series       = {Annals of the Rheumatic Diseases},
  title        = {EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis},
  url          = {http://dx.doi.org/10.1136/annrheumdis-2016-209133},
  volume       = {75},
  year         = {2016},
}